BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 8018564)

  • 1. Max activity is affected by phosphorylation at two NH2-terminal sites.
    Koskinen PJ; Västrik I; Mäkelä TP; Eisenman RN; Alitalo K
    Cell Growth Differ; 1994 Mar; 5(3):313-20. PubMed ID: 8018564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of casein kinase II phosphorylation sites in Max: effects on DNA-binding kinetics of Max homo- and Myc/Max heterodimers.
    Bousset K; Henriksson M; Lüscher-Firzlaff JM; Litchfield DW; Lüscher B
    Oncogene; 1993 Dec; 8(12):3211-20. PubMed ID: 8247525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of sequences responsible for the differential regulation of Myc function by delta Max and Max.
    Västrik I; Mäkelä TP; Koskinen PJ; Alitalo K
    Oncogene; 1995 Aug; 11(3):553-60. PubMed ID: 7630640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of Mxi1 inhibits the induction of the human ornithine decarboxylase gene by the Myc/Max protein complex.
    Wu S; Peña A; Korcz A; Soprano DR; Soprano KJ
    Oncogene; 1996 Feb; 12(3):621-9. PubMed ID: 8637719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The C. elegans MDL-1 and MXL-1 proteins can functionally substitute for vertebrate MAD and MAX.
    Yuan J; Tirabassi RS; Bush AB; Cole MD
    Oncogene; 1998 Sep; 17(9):1109-18. PubMed ID: 9764821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mmip1: a novel leucine zipper protein that reverses the suppressive effects of Mad family members on c-myc.
    Gupta K; Anand G; Yin X; Grove L; Prochownik EV
    Oncogene; 1998 Mar; 16(9):1149-59. PubMed ID: 9528857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure, function, and dynamics of the dimerization and DNA-binding domain of oncogenic transcription factor v-Myc.
    Fieber W; Schneider ML; Matt T; Kräutler B; Konrat R; Bister K
    J Mol Biol; 2001 Apr; 307(5):1395-410. PubMed ID: 11292350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The NMR solution structure of a mutant of the Max b/HLH/LZ free of DNA: insights into the specific and reversible DNA binding mechanism of dimeric transcription factors.
    Sauvé S; Tremblay L; Lavigne P
    J Mol Biol; 2004 Sep; 342(3):813-32. PubMed ID: 15342239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of cancer cell growth and c-Myc transcriptional activity by a c-Myc helix 1-type peptide fused to an internalization sequence.
    Giorello L; Clerico L; Pescarolo MP; Vikhanskaya F; Salmona M; Colella G; Bruno S; Mancuso T; Bagnasco L; Russo P; Parodi S
    Cancer Res; 1998 Aug; 58(16):3654-9. PubMed ID: 9721875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transfected wild-type and mutant max regulate cell growth and differentiation of murine erythroleukemia cells.
    Cogliati T; Dunn BK; Bar-Ner M; Cultraro CM; Segal S
    Oncogene; 1993 May; 8(5):1263-8. PubMed ID: 8479748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. c-Myc inactivation by mutant Max alters growth and morphology of NCI-H-630 colon cancer cells.
    Borrè A; Cultraro CM; Segal S
    J Cell Physiol; 1996 Oct; 169(1):200-8. PubMed ID: 8841436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene-regulatory properties of Myc helix-loop-helix/leucine zipper mutants: Max-dependent DNA binding and transcriptional activation in yeast correlates with transforming capacity.
    Crouch DH; Fisher F; Clark W; Jayaraman PS; Goding CR; Gillespie DA
    Oncogene; 1993 Jul; 8(7):1849-55. PubMed ID: 8510929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. c-Myc does not require max for transcriptional activity in PC-12 cells.
    Ribon V; Leff T; Saltiel AR
    Mol Cell Neurosci; 1994 Jun; 5(3):277-82. PubMed ID: 8087425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mad1 expression in the absence of differentiation: effect of cAMP on the B-lymphoid cell line Reh.
    Naderi S; Blomhoff HK
    J Cell Physiol; 1999 Jan; 178(1):76-84. PubMed ID: 9886493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the DNA-binding activities of Myc/Max/Mad network complexes during induced differentiation of U-937 monoblasts and F9 teratocarcinoma cells.
    Larsson LG; Bahram F; Burkhardt H; Lüscher B
    Oncogene; 1997 Aug; 15(6):737-48. PubMed ID: 9264414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Both the helix-loop-helix and the leucine zipper motifs of c-Myc contribute to its dimerization specificity with Max.
    Davis LJ; Halazonetis TD
    Oncogene; 1993 Jan; 8(1):125-32. PubMed ID: 8423990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The basic region/helix-loop-helix/leucine zipper domain of Myc proto-oncoproteins: function and regulation.
    Lüscher B; Larsson LG
    Oncogene; 1999 May; 18(19):2955-66. PubMed ID: 10378692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insights into the mechanism of heterodimerization from the 1H-NMR solution structure of the c-Myc-Max heterodimeric leucine zipper.
    Lavigne P; Crump MP; Gagné SM; Hodges RS; Kay CM; Sykes BD
    J Mol Biol; 1998 Aug; 281(1):165-81. PubMed ID: 9680483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low molecular weight inhibitors of Myc-Max interaction and function.
    Yin X; Giap C; Lazo JS; Prochownik EV
    Oncogene; 2003 Sep; 22(40):6151-9. PubMed ID: 13679853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of transcriptional repression by max homodimers.
    Yin X; Grove L; Prochownik EV
    Oncogene; 1998 May; 16(20):2629-37. PubMed ID: 9632139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.